Figure 3.
Representation of AEs occurring at a prevalence of >2% among 109 patients diagnosed with high-risk DLBCL in complete remission, treated with atezolizumab for up to 54 weeks.

Representation of AEs occurring at a prevalence of >2% among 109 patients diagnosed with high-risk DLBCL in complete remission, treated with atezolizumab for up to 54 weeks.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal